SAFETY, TOLERABILITY, AND BIOLOGIC ACTIVITY OF L 733,723 IN PSORIATIC PATIENTS

这是一项针对中度糖尿病患者的多中心、多剂量研究。 严重银屑病(随机、安慰剂对照、双盲、 串行4面板设计)。剂量水平最初包括0.15毫克/公斤、0.30毫克/公斤 Mg，0.45 mg/kg，q12小时。持续2周。根据这些研究的结果， 研究药物的最佳给药方案是选择和 环孢素治疗8周。然而，根据第一部分的结果， 在这项研究中，对方案的第二部分进行了修改。越高 治疗时间为 延长至12周。该协议作为一个多中心继续存在 随机、双盲、平行组多剂量口服研究 L-733725与环孢素的耐受性及疗效评价 A组与安慰剂组治疗中重度白血病的对比研究 慢性斑块型银屑病。

This was a multi-center, multiple dose study in patients with moderate to severe psoriasis (a randomized, placebo-controlled, double-blind, serial 4 panel design). Dose levels included initially 0.15 mg/kg, 0.30 mg, and 0.45 mg/kg q 12 hr. for 2 weeks. Based on results from these, the best dosage schedule for the study drug was to be chosen and patients were to be randomized to receive study drug, placebo or cyclosporine for 8 weeks. However, based on results from the first part of the study the second part of the protocol was modified. The higher dose was reduced to 0.26 mg/kg q 12 hr. and the treatment time was extended to 12 weeks. This protocol was continued as a multicenter randomized, double-blinded, parallel-group multiple oral dose study to evaluate the tolerability and efficacy of L-733725 versus cyclosporine A versus placebo in the treatment of patients with moderate to severe chronic plaque-type psoriasis.